On July 6, 2023, the Food and Drug Administration (FDA) provided approval for lecanemab (Leqembi) to treat early-stage Alzheimer’s disease. Lecanemab is a medication developed by Eisai and Biogen that may help slow the progression of early stage Alzheimer’s disease. Many people living with dementia...
Resource Center Item
- 9/8/2023